WHO ICTRP trial
Single Dose Study of MK-6482 in Healthy Japanese Female Participants
JPRN-jRCT2031220024 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031220024 |
|---|---|
| Public title | Single Dose Study of MK-6482 in Healthy Japanese Female Participants |
| Scientific title | A single-dose clinical study to evaluate the pharmacokinetics of belzutifan (MK-6482) in healthy Japanese female participants |
| Primary sponsor | Tanaka Yoshiyuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Conditions | Renal Cell Carcinoma |
| Interventions | - Palens A and C Single dose of MK-6482 80 mg will be administerd. - Palens B and D Single dose of MK-6482 120 mg will be administerd. |
| Registration date | Apr 16, 2022 |
| Target size | 24 |
| Secondary IDs | Nil known |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: